Skip to main content

Severe Immunosuppression

Last updated 18 September 2023

People with a severely weakened immune system are eligible for a primary course of COVID vaccine and subsequent booster doses.

Severe Immunosuppression

Based on the latest UK national guidance set out in the "Green Book" (COVID-19: the green book, chapter 14a - GOV.UK (www.gov.uk)) the following individuals aged 6 months + with severe immunosuppression are eligible booster:

  • Immunosuppression due to disease or treatment, including patients undergoing chemotherapy leading to immunosuppression, patients  undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID).

  • Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil.

  • Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults.

  • Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma.

  • Those who require long term immunosuppressive treatment for conditions including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, scleroderma and psoriasis. 

Connect: